Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APOMORPHINE HYDROCHLORIDE vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-ergoline dopamine agonist with high affinity for D2 and D3 receptors, moderate affinity for D4, D5, and adrenergic receptors; activates striatal dopamine receptors to improve motor function.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
FDA: Acute treatment of hypomobility episodes ('off' episodes) in Parkinson disease,Off-label: Refractory erectile dysfunction, treatment of levodopa-induced dyskinesias, depression
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
Subcutaneous injection: 0.2 m L (2 mg) test dose, then 0.2-0.6 m L (2-6 mg) as needed for acute hypomobility episodes; maximum single dose 0.6 m L (6 mg). Sublingual: 2-10 mg sublingually as needed, not more than every 2 hours, maximum 30 mg/day. Continuous subcutaneous infusion: 0.5-2.0 mg/hour via infusion pump.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life is 40–60 minutes in adults with normal renal function; prolonged to 3–6 hours in end-stage renal disease.
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Hepatic via CYP3A4, CYP2C9, and CYP2C19; main metabolite is apomorphine-8-O-sulfate; first-pass effect with rapid clearance.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Approximately 90% of an intravenous dose is excreted in urine within 24 hours, primarily as unchanged drug and sulfate conjugates. Biliary/fecal excretion is minimal (<5%).
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Approximately 90–99% bound, primarily to albumin.
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
1.8–2.5 L/kg, indicating extensive tissue distribution.
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Subcutaneous: 100% (absolute); sublingual: 16–18%; oral: <1% due to extensive first-pass metabolism.
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
No dose adjustment for mild to moderate impairment. Severe impairment (GFR <15 m L/min): avoid use as apomorphine is renally eliminated and accumulation may occur; use with caution and reduce dose if necessary at GFR 15-29 m L/min.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh A and B: no dose adjustment necessary. Child-Pugh C: pharmacokinetics not studied; use with caution and monitor closely.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Safety and efficacy not established; no pediatric dosing recommendations.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Elderly patients may be more sensitive to neuropsychiatric effects; initiate at low end of dosing range (e.g., 1-2 mg subcutaneously) and titrate slowly; monitor for hypotension and falls.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
None.
None.
Risk of hypotension, syncope, and orthostatic hypotension,Severe nausea and vomiting (pretreat with antiemetic),Potential for hallucination, dyskinesia, and impulse control disorders,Do not mix with serotonin 5-HT3 antagonists (e.g., ondansetron) due to severe hypotension,Use caution in patients with cardiovascular disease, hypotension, or renal impairment
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Concurrent use with serotonin 5-HT3 antagonists (e.g., ondansetron),Hypersensitivity to apomorphine or sulfite-containing products,Severe asthma or sulfite allergy
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid alcohol: may increase drowsiness and hypotension. Grapefruit juice: may increase risk of QT prolongation. No specific food interactions; maintain normal diet but monitor for changes in blood pressure.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
Apomorphine hydrochloride is a dopamine agonist indicated for Parkinson's disease. Limited human pregnancy data; animal studies show fetotoxicity and teratogenicity at doses near maternal toxic doses. FDA Pregnancy Category C. First trimester: Avoid use unless benefit outweighs risk. Second/third trimester: No established safety; potential fetal effects include altered dopamine receptor development. Postnatal: Risk of neonatal withdrawal if used near term.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
No data on apomorphine excretion in human milk. M/P ratio unknown. Due to potential for serious adverse reactions in breastfeeding infants (e.g., somnolence, hypotension, dyskinesia), breastfeeding is not recommended during therapy.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
Pregnancy can alter apomorphine pharmacokinetics due to increased plasma volume, renal blood flow, and hepatic metabolism. No specific dose adjustment guidelines exist. Use lowest effective dose with careful titration. Monitor for reduced efficacy or increased adverse effects (e.g., hypotension, nausea).
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Administer subcutaneously; avoid intravenous use due to risk of hemolytic anemia and hypotension. Onset is rapid (5-15 minutes) with short duration (1 hour). Use an antiemetic (e.g., domperidone or trimethobenzamide) for 3 days before starting to prevent nausea. Do not use with 5-HT3 antagonists (e.g., ondansetron) due to profound hypotension. Monitor for dyskinesia, orthostatic hypotension, and QT prolongation. Avoid in patients with dementia, psychosis, or severe respiratory depression; caution in hepatic/renal impairment. Test dose (0.2-0.5 m L) is required before first prescription.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Take this medication exactly as prescribed; it is for on-demand treatment of 'off' episodes.,Inject under the skin (subcutaneous) as directed; do not inject into a vein or muscle.,You may feel dizzy or lightheaded when standing up; rise slowly from sitting or lying down.,Nausea is common; your doctor may prescribe an anti-nausea medicine to take before each dose.,Report any chest pain, fainting, or severe dizziness immediately.,Avoid alcohol and grapefruit juice while using this medication.,Do not change your dose or frequency without consulting your doctor.,Keep this medication away from children and pets.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
"Coadministration of morphine with palbociclib may increase plasma concentrations of palbociclib due to morphine-induced inhibition of intestinal P-glycoprotein (P-gp) efflux transporter and potential competition for CYP3A4 metabolism. This elevation can heighten the risk of palbociclib-related toxicities, including myelosuppression (neutropenia, leukopenia, anemia), hepatotoxicity, and gastrointestinal adverse effects (e.g., diarrhea, nausea). Patients should be monitored for signs of excessive palbociclib exposure and dose reductions considered if toxicity occurs."
"Morphine, a potent opioid analgesic, can inhibit the metabolism of sulfisoxazole, a sulfonamide antibiotic, by competing for hepatic glucuronidation pathways. This pharmacokinetic interaction leads to increased plasma concentrations of sulfisoxazole, potentially elevating the risk of dose-dependent adverse effects such as crystalluria, hypersensitivity reactions, and bone marrow suppression. Co-administration requires careful monitoring for sulfonamide toxicity, especially in patients with renal impairment or those receiving high-dose morphine."
"Morphine is a potent opioid analgesic that can inhibit the metabolism of isavuconazonium (prodrug of isavuconazole) via competitive inhibition of CYP3A4, the primary enzyme responsible for its activation. This leads to reduced conversion to the active antifungal isavuconazole, potentially decreasing its efficacy against invasive fungal infections. Conversely, isavuconazonium may also inhibit morphine metabolism, increasing opioid side effects such as respiratory depression, sedation, and constipation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APOMORPHINE HYDROCHLORIDE vs ACTIFED, answered by our medical review team.
APOMORPHINE HYDROCHLORIDE is a Opioid Agonist that works by Non-ergoline dopamine agonist with high affinity for D2 and D3 receptors, moderate affinity for D4, D5, and adrenergic receptors; activates striatal dopamine receptors to improve motor function.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APOMORPHINE HYDROCHLORIDE and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APOMORPHINE HYDROCHLORIDE is: Subcutaneous injection: 0.2 m L (2 mg) test dose, then 0.2-0.6 m L (2-6 mg) as needed for acute hypomobility episodes; maximum single dose 0.6 m L (6 mg). Sublingual: 2-10 mg sublingually as needed, not more than every 2 hours, maximum 30 mg/day. Continuous subcutaneous infusion: 0.5-2.0 mg/hour via infusion pump.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APOMORPHINE HYDROCHLORIDE and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APOMORPHINE HYDROCHLORIDE is classified as Category D/X. Apomorphine hydrochloride is a dopamine agonist indicated for Parkinson's disease. Limited human pregnancy data; animal studies show fetotoxicity and teratogenicity at doses near m. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.